Clene Inc. (CLNN)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$6.0M
Cash & Equivalents
$4.5M
Quarterly Burn Rate
4 mo
Est. Cash Runway
$80M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT05299658 An Open-Label Extension for the Phase 2 Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Back... PHASE2 Active Not Recruiting 40

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for CLNN.

SEC EDGAR Filings

All SEC filings for Clene Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.